Through many months’ preparation, Actor SphygmoCor XCEL Cardiac and Renal Function Measurement System was launched at the 71st China International Medical Equipment Fair (CMEF) from April 17th to 20th, 2014.

So far, SphymoCor XCEL is the only device globally for comprehensive management of the patients with renal disease. Originally imported from Australia, SphymoCor XCEL can measure multiple parameters of the patients so as to evaluate the CV risk, instruct accurate medication and follow up the treatment effect of the nephritic patients:

Non-invasive Central Arterial Pressure（CAP）

Central Pulse Pressure （CPP）

Augmentation Pressure （AP）

Augmentation Index （Aix）

Carotid-Femoral Pulse Wave Velocity（cfPWV）

At the night before launching，the representative of the manufacturer provided comprehensive training to Angy’s sales team, explaining the features of SphygmoCor XCEL in detail and providing instructions on how to operate the device in person.

Evaluating CV risk of the nephritic patients：predicting  aortic calcification risk; evaluating CV risk in stage 4 and 5 CKD；detecting early-stage artery stiffness .

Instructing medication: Guiding physicians or patients to choose calcium binder or other medicine; determining responders in ESRD so as to determine appropriate anti-hypertensive drugs to reduce CV risk.

Following up the treatment effect: measuring patient’s compliance with anti-hypertensive drugs to maintain kidney function and delay dialysis; determining whether the anti-hypertensive drugs have met each patient’s individual BP reduction goal.

During the exhibition, Angy’s splendid booth attracted plenty of visitors. With leading technology advantages, unique measurement parameters and gorgeous design, SphygmoCor XCEL attracted a lot of visitors (included physicians, distributors and patients) to have a try on the product. They all spoke highly of the products in terms of accuracy and repeatability and gladly accepted the clinical suggestions based on the measurement parameters.      

On the night of April 18th, during Angy’s dinner party, the vice president from Actor Medical and the marketing manager of cardiovascular product from Angy briefly introduced SpygmoCor XCEL to the partners throughout China, which gained warm applause from the partners present.

In the near future, it is promising that the application of SphygmoCor XCEL in China will upgrade the medical level in a further step so as to bring benefits for the senior group, the nephritic patients and CV patients.